Stammdaten
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Unternehmen & Branche
| Name | GUIDED THERAPEUTICS INC |
|---|---|
| Ticker | GTHP |
| CIK | 0000924515 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 14,6 Mio. USD |
| Beta | 0,75 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 767,000 | -3,196,000 | -0.04 | 1,324,000 | -6,006,000 |
| 2025-09-30 | 10-Q | 60,000 | -742,000 | -0.01 | 903,000 | -5,646,000 |
| 2025-06-30 | 10-Q | 117,000 | -811,000 | -0.01 | 940,000 | -5,472,000 |
| 2025-03-31 | 10-Q | 0 | -427 | -0.01 | 967,000 | -5,028,000 |
| 2024-12-31 | 10-K | 7,000 | -2,417,000 | -0.05 | 1,378,000 | -4,889,000 |
| 2024-09-30 | 10-Q | 0 | -654,000 | -0.01 | 1,249,000 | -4,918,000 |
| 2024-06-30 | 10-Q | 0 | -709,000 | -0.01 | 1,251,000 | -4,667,000 |
| 2024-03-31 | 10-Q | 6,000 | -402 | -0.01 | 1,494,000 | -4,012,000 |
| 2023-12-31 | 10-K | 98,000 | -3,489,000 | -0.07 | 1,669,000 | -3,806,000 |
| 2023-09-30 | 10-Q | 0 | -677,000 | -0.01 | 1,877,000 | -3,650,000 |
| 2023-06-30 | 10-Q | 44,000 | -1,557,000 | -0.03 | 2,348,000 | -3,315,000 |
| 2023-03-31 | 10-Q | 22,000 | -869,000 | -0.02 | 2,892,000 | -2,855,000 |
| 2022-12-31 | 10-K | 13,000 | -4,341,000 | -0.15 | 3,366,000 | -2,883,000 |
| 2022-09-30 | 10-Q | 3,000 | -1,102,000 | -0.03 | 3,871,000 | -2,651,000 |
| 2022-06-30 | 10-Q | 5,000 | -926,000 | -0.04 | 1,503,000 | -5,766,000 |
| 2022-03-31 | 10-Q | 5,000 | -507,000 | -0.05 | 2,187,000 | -4,988,000 |
| 2021-12-31 | 10-K | 81,000 | -2,070,000 | -0.18 | 2,040,000 | -5,445,000 |
| 2021-09-30 | 10-Q | 19,000 | 68,000 | 0.00 | 1,744,000 | -7,746,000 |
| 2021-06-30 | 10-Q | 2,000 | -1,034,000 | -0.09 | 2,067,000 | -7,992,000 |
| 2021-03-31 | 10-Q | 0 | -517,000 | -0.04 | 2,362,000 | -7,992,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-29 | Imhoff John E | Director, 10% Owner | Open Market Purchase | 166,667 | 0.18 | 30,000.06 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.